Summit Therapeutics (NASDAQ:SMMT) and Myovant Sciences (NYSE:MYOV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability. Profitability This table compares Summit Therapeutics and Myovant Sciences net margins, return on equity and []

Myovant Sciences (NYSE:MYOV) Hits New 52-Week Low at $13.91

07:56am, Thursday, 09'th Dec 2021 Dakota Financial News
Myovant Sciences Ltd. (NYSE:MYOV)s share price reached a new 52-week low during trading on Tuesday . The stock traded as low as $13.91 and last traded at $15.09, with a volume of 1989213 shares changing hands. The stock had previously closed at $14.66. Several equities research analysts have commented on the company. SVB Leerink dropped []
Myovant Sciences Ltd. (NYSE:MYOV) insider Ferreira Juan Camilo Arjona sold 1,978 shares of the businesss stock in a transaction dated Monday, November 29th. The shares were sold at an average price of $19.30, for a total value of $38,175.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is []

Myovant Sciences (NYSE:MYOV) Sets New 52-Week Low After Insider Selling

08:48am, Friday, 03'rd Dec 2021 Dakota Financial News
Myovant Sciences Ltd. (NYSE:MYOV) shares hit a new 52-week low on Wednesday following insider selling activity. The company traded as low as $16.50 and last traded at $16.51, with a volume of 1372 shares changing hands. The stock had previously closed at $16.81. Specifically, major shareholder Chemical Co. Ltd. Sumitomo bought 89,864 shares of the []

Myovant Sciences Ltd Shares Near 52-Week Low - Market Mover

10:48pm, Tuesday, 30'th Nov 2021 Kwhen Finance
Myovant Sciences Ltd (MYOV) shares closed today at 0.7% above its 52 week low of $16.69, giving the company a market cap of $1B. The stock is currently down 32.4% year-to-date, down 20.7% over the past 12 months, and up 45.1% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 0.6%. Trading Activity Trading volume this week was 29.4% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 0.6% The company's stock price performance over the past 12 months beats the peer average by -26.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Myovant Sciences (NYSE:MYOV) Stock Price Down 9.1%

08:38pm, Tuesday, 30'th Nov 2021 Dakota Financial News
Myovant Sciences Ltd. (NYSE:MYOV) shares fell 9.1% during mid-day trading on Tuesday . The company traded as low as $16.96 and last traded at $16.96. 26,840 shares changed hands during trading, a decline of 96% from the average session volume of 752,421 shares. The stock had previously closed at $18.66. A number of brokerages have […]
Wall Street brokerages predict that Myovant Sciences Ltd. (NYSE:MYOV) will announce sales of $56.34 million for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Myovant Sciences earnings, with estimates ranging from $53.28 million to $58.40 million. Myovant Sciences posted sales of $1.38 million in the same quarter last year, which []
During the last session, Myovant Sciences Ltd. (NYSE:MYOV)s traded shares were 0.69 million, with the beta value of the company hitting 2.72. At the end of the trading day, the stocks price was $19.93, reflecting an intraday gain of 2.21% or $0.43. The 52-week high for the MYOV share is $30.90, that puts it down How Myovant Sciences Ltd. (NYSE: MYOV) Could Be A Loss Maker Since It Is Down -27.84% YTD? Read More »

Millennium Management LLC Increases Position in Myovant Sciences Ltd. (NYSE:MYOV)

11:00am, Wednesday, 24'th Nov 2021 Dakota Financial News
Millennium Management LLC lifted its position in shares of Myovant Sciences Ltd. (NYSE:MYOV) by 1,467.6% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 219,459 shares of the companys stock after buying an additional 205,459 shares during the period. Millennium Management LLCs holdings in Myovant Sciences were worth []
BASEL, Switzerland, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the Evercore ISI 4th
BASEL, Switzerland, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021. David Marek, Chief Executive Officer of Myovant Sciences, Inc. will participate in a fireside chat at 11:45 a.m. Eastern Time.

-$0.56 EPS Expected for Myovant Sciences Ltd. (NYSE:MYOV) This Quarter

06:10pm, Monday, 22'nd Nov 2021 Dakota Financial News
Equities research analysts expect Myovant Sciences Ltd. (NYSE:MYOV) to post earnings per share of ($0.56) for the current quarter, according to Zacks. Three analysts have made estimates for Myovant Sciences’ earnings, with the lowest EPS estimate coming in at ($0.64) and the highest estimate coming in at ($0.50). Myovant Sciences reported earnings per share of […]
Equities analysts expect that Myovant Sciences Ltd. (NYSE:MYOV) will announce earnings per share (EPS) of ($0.56) for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Myovant Sciences earnings, with estimates ranging from ($0.64) to ($0.50). Myovant Sciences posted earnings of ($0.82) per share in the same quarter last year, which []

Boom Or Bust: What Is Next For Myovant Sciences Ltd. (NYSE: MYOV) Stock?

02:00pm, Saturday, 20'th Nov 2021 Marketing Sentinel
Myovant Sciences Ltd. (NYSE:MYOV)s traded shares stood at 0.4 million during the last session, with the companys beta value hitting 2.73. At the close of trading, the stocks price was $20.24, to imply a decrease of -0.93% or -$0.19 in intraday trading. The MYOV shares 52-week high remains $30.90, putting it -52.67% down since that Boom Or Bust: What Is Next For Myovant Sciences Ltd. (NYSE: MYOV) Stock? Read More »
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE